Generics give injectables a shot


Vial and syringe

Sterile injectables are difficult to manufacture well, but the market is growing © Shutterstock

Generics companies are scrabbling for footholds in the world of sterile injectable products. A rash of deals has seen India’s Lupin Pharmaceuticals and Aurobindo, as well as US firms Par Pharmaceuticals and Mylan, go for bigger slices of the multi-billion pound market.

On 3 February, Lupin agreed to buy Nanomi, an injectables specialist based in the Netherlands, for an undisclosed amount. In January, Aurobindo finalised a deal with Actavis to take over chunks of its European operations, including a platform to launch injectable products based on Actavis’s hospital sales infrastructure.

In the US, Par Pharmaceuticals’ $490 million (£300 million) buyout of injectables expert JHP Pharmaceuticals follows on from a string of similar deals last year, notably Mylan’s takeover of Agila injectables, worth up to $1.75 billion, bolstering Mylan’s position as a major injectables producer.

Injectables is an attractive growing market, linked to growth in complex biological drugs – particularly as generic biosimilar versions start to be approved. Most of these products are unsuitable for formulating as tablets, so need to be injected. Diabetes and cancer treatments are also commonly injected, and with ageing populations demand for these medicines is increasing steadily.

But manufacturing injectables is a tricky business, as shown by a steady stream of quality concerns, failed manufacturing inspections and ensuing product shortages. That means the barriers to entry are high – hence new players are buying their way in through acquisitions rather than starting from scratch.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

30 June 2011 Business

news image

Industry news, July 2011

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Chemistry behind the ‘blue man’ unlocked

1 November 2012 Research

news image

Biochemical model suggests that silver ions, not nanoparticles, cause a rare skin complaint